Guillain-Barré syndrome epidemiology and demographics: Difference between revisions

	Guillain-Barré syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Guillain-Barré syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Guillain-Barré syndrome epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Guillain-Barré syndrome epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Guillain-Barré syndrome epidemiology and demographics
CDC on Guillain-Barré syndrome epidemiology and demographics
Guillain-Barré syndrome epidemiology and demographics in the news
Blogs on Guillain-Barré syndrome epidemiology and demographics
Directions to Hospitals Treating Guillain-Barré syndrome
Risk calculators and risk factors for Guillain-Barré syndrome epidemiology and demographics

VisualWikitext

Revision as of 22:04, 17 February 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. The incidence is approximately 1.2 - 3 / 100,000 persons per year across the world. It is commoner in males compared to female and has two peaks (15-35 years and 50-75 years). Incidence is similar across different races.

Epidemiology and demographics

USA

It is the commonest cause of acute, flaccid paralysis in USA.
Incidence- 1.2 - 3 / 100,000 persons

International

It has been reported all over the world.
The incidence is around 1.5 - 3 / 100,000 persons
The antecedence of Clostridum jejuni is commoner in Japan and other Asian countries. Whereas, in American continents and European nation an antecedence of cytomegalovirus is common.

Age

Incidence increases with age.
Bimodal distribution - First peak during 15 - 35 yrs and second during old age.
New-borns and infants have the least risks of development of GBS

Race

Incidence is similar across different races.

Gender

It occurs more commonly in males compared to females. Male to female ratio 1.5:1
The incidence has been found to increase post-partum and decreases during pregnancy

References

Template:WH Template:WS

@@ Line 6: / Line 6: @@
 ==Overview==
-'''Guillain-Barré syndrome''' ('''GBS''') is an acute, autoimmune, [[neuropathy|polyradiculoneuropathy]] affecting the [[peripheral nervous system]], usually triggered by an acute infectious process. It is included in the wider group of [[peripheral neuropathy|peripheral neuropathies]]. There are several types of GBS, but unless otherwise stated, GBS refers to the most common form, acute inflammatory demyelinating polyneuropathy (AIDP). It is frequently severe and usually exhibits as an ascending paralysis noted by weakness in the legs that spreads to the upper limbs and the face along with complete loss of deep tendon reflexes. With prompt treatment of [[plasmapheresis]] followed by [[immunoglobulins]] and supportive care, the majority of patients will regain full functional capacity. However, death may occur if severe pulmonary complications and [[dysautonomia]] are present.
+'''Guillain-Barré syndrome''' ('''GBS''') is an acute, autoimmune, [[neuropathy|polyradiculoneuropathy]] affecting the [[peripheral nervous system]], usually triggered by an acute infectious process. The incidence is approximately 1.2 - 3 / 100,000 persons per year across the world. It is commoner in males compared to female and has two peaks (15-35 years and 50-75 years). Incidence is similar across different races.
 ==Epidemiology and demographics==
 ===USA===